Windsor-Detroit trade needs enhanced security: Pupatello speaks out
Senator Sandra Pupatello is raising alarm bells when it comes to gaps in Canada's security, specifically concerning the protection of waterways in Essex County and the Windsor-Detroit trade corridor.
At Wednesday's Senate Finance Committee meeting, Pupatello was able to make remarks directed at both the Ministry of Public Safety and the Ministry of Defense, both of which are seeking increased spending to enhance security and trade protections.
Pupatello told AM800's The Shift with Patty Handysides that she believes the money should be invested in the Windsor-Essex region.
'I'm concerned that we have a much better focus on the epicentre, especially considering the tariffs we're facing because our American friends are insisting that they see an enhanced environment for guns, for drugs, protecting our citizenry, this is the time for an investment right here,' said Pupatello.
Pupatello says she feels there's a lack of coordination between agencies through the Windsor-Detroit corridor.
'It is the epicentre of trade for North America. We have 25 per cent of Canada's trade with America going right through Windsor-Detroit, and if you were to understand how many agencies are involved, and yet, there is zero coordination amongst them to guarantee that we have 24/7 coverage, some of the details I think are pretty shocking,' she said.
Pupatello is calling for at minimum, enhanced electronic surveillance.
'I see a capital spend coming down the road, where is that going to go? I think this should be the epicentre of those kinds of investments. If we get it right in Windsor-Detroit, the most prominent trade corridor in the continent, we're going to get it right everywhere else,' Pupatello said.
She added she is committed to closely monitor the plans that the Ministry of Defense and the Ministry of Public Safety will develop, particularly their request of billions in additional funding.
— Duston Coffman/AM800 News
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
30 minutes ago
- Globe and Mail
Canada is not for sale – and neither are our skies
Ajay Virmani CM is the founder and executive chair of Cargojet. Thursday's recommendations from the Competition Bureau to open Canada's skies to foreign airlines may sound like a pro-consumer move. But beneath the surface, the move risks undermining our aviation industry, threatening Canadian jobs, and handing over control of a vital sector – all without getting a single thing in return. The bureau suggests allowing foreign carriers to fly domestic routes in Canada – a move known as 'cabotage' – and phasing out foreign ownership restrictions entirely. If adopted, these changes would fundamentally alter the aviation landscape in Canada. And not for the better. Watchdog says Ottawa should allow foreign-owned airlines to fly domestic routes to boost competition Let's start with the obvious: There is no reciprocal access. The foreign carriers most likely to cash in on this opportunity will be American ones, because of geography. But the United States, our closest trading partner, does not allow foreign carriers to operate domestic routes. It guards that privilege closely – as does many other major nations. Why, then, should Canada unilaterally open our skies? Competition is healthy – but only when it's fair. We cannot be the only country willing to give away our market while others protect theirs. That's not strategy – that's surrender. Canada is a country of extremes. We are the second-largest nation by landmass, but with a population spread thinly across vast geography. Air travel isn't just a convenience – it's a necessity. But let's be blunt: Canada is not big enough to support even three major airlines as the past two decades have shown. More than 15 carriers – from Jetsgo to Lynx – have gone out of business trying. Foreign airlines, with deep pockets and no long-term obligation to our infrastructure, will swoop in to cherry-pick profitable urban routes – Toronto to Vancouver, Montreal to Calgary – and leave Canadian carriers to subsidize unprofitable regional and remote routes. When the local players fold, who will serve the North? Who will fly to the small towns? Prices will go up, and service will disappear. The impact won't just be felt in boardrooms – it will hit everyday Canadians across the aviation workforce. We're talking about pilots, engineers, mechanics, technology professionals, baggage handlers, call centre teams and support staff. Foreign carriers have no incentive to hire in Canada beyond what's absolutely necessary. Opening the door to foreign dominance means exporting opportunity, experience and expertise – and leaving a skilled Canadian workforce behind. In today's geopolitical climate, the last thing we should do is hand over our aviation sector to foreign ownership. Aviation isn't just another business – it's a strategic asset. In emergencies, natural disasters and national defence, a strong domestic aviation backbone matters. Foreign ownership comes with no such loyalty. If the government truly wants to improve Canadian aviation, it should start with what's in its control: modernize our airports, lower sky-high airport rents and fees, invest in regional infrastructure and overhaul NAV Canada, which operates our civil air navigation system. These structural issues are what make flying in Canada expensive – not a lack of foreign players. Opinion: Stop the charade. Ottawa isn't prepared to do what it takes to improve airline competition Opening the door to foreign carriers without fixing the broken foundation is like inviting guests into a crumbling house and hoping they'll renovate it for you. The promise of cheaper fares is always tempting. But the reality is, foreign carriers will skim the cream off the top – and leave Canadian operators to handle the rest. Once Canadian carriers are weakened or gone, what leverage will we have left? The decisions will be made in boardrooms far away, with no regard for Canadian jobs, service standards, or national resilience. We need smart competition, not blind deregulation. We need policy that supports homegrown carriers and gives them the tools to grow and compete globally. And we need to recognize that our aviation sector isn't just about profits – it's about sovereignty, accessibility and nation-building. Canada is not for sale – and neither are our skies. Let's not let short-term thinking cost us our long-term future.
Globe and Mail
30 minutes ago
- Globe and Mail
Velomax Distribution Delivers What Amazon FBA Sellers Need: Fast-Selling Branded Products, Verified Suppliers, and Profitable ROI
For Amazon FBA sellers looking to scale without the headaches, Velomax Distribution is becoming a trusted source for profitable, fast-moving inventory. They don't overpromise. Instead, they focus on what actually works — real product research, curated wholesale catalogs, and a system built around speed, transparency, and results. 'Our goal is to help you source inventory that actually sells,' says a Velomax team member. Unlike suppliers who only push brand-owned listings or Amazon-dominated products, Velomax focuses on what's already selling for FBA sellers like you. Backed by real data and hands-on experience, they understand how the market works — and they make it easy for sellers to plug into winning products. Sellers get Amazon-compliant invoices, trend-backed product suggestions, and the flexibility to grow without being locked into confusing service models. For updates, follow Velomax Distribution on Facebook: About Velomax Distribution With over seven years of combined experience in sales, logistics, and distribution, Velomax Distribution has built a system focused on speed, quality, and scalability. Velomax maintains a transparent business model by sourcing products directly from manufacturers and trusted suppliers, then selling to retailers at wholesale prices with prompt delivery. They accept multiple payment methods including wire transfers, ACH, and credit cards, while maintaining minimum order quantities that vary by product and brand. The company provides a fully transparent supply chain with invoices issued from brand to company and company to customer, though supplier authorization depends on individual brand requirements. Their customer-focused approach includes processing most orders within 1-3 business days, with delivery typically taking 3-7 business days within the U.S., plus a return policy for damaged, defective, or incorrectly shipped products within 7-14 days of delivery. For those seeking a true distribution partner — not just another middleman — Velomax Distribution is the right choice. Velomax Distribution is making wholesale easier. Learn more at: Media Contact Company Name: Velomax Distribution Contact Person: Support Email: Send Email City: Miami State: Florida Country: United States Website:
Globe and Mail
30 minutes ago
- Globe and Mail
Blood Plasma Market to Witness Strong Growth at 10.8% CAGR, Expected to Hit USD 79.5 Mn by 2032
The trend in the blood plasma industry is characterized by a growing focus on research and development activities to develop novel plasma-derived therapies, increasing collaboration between plasma collection centers and pharmaceutical companies, and the expansion of plasma collection networks worldwide. Additionally, there is a growing emphasis on improving the safety and quality of plasma-derived products through stringent regulatory guidelines and advanced testing methodologies. Blood Plasma Market Insights The blood plasma industry has witnessed robust expansion driven by rising therapeutic demand and advanced manufacturing processes. Experts leverage novel fractionation techniques to meet growing immunoglobulin and albumin requirements, reflecting deep market research and market insights underpinning strategic decisions. The Global Blood Plasma Market size is estimated to be valued at USD 38.8 Mn in 2025 and is expected to reach USD 79.5 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 10.8% from 2025 to 2032. Market Key Takeaways - Region: - North America: robust regulatory framework and extensive donor networks enhance plasma availability. - Latin America: emerging collection centers in Brazil and Argentina drive capacity expansion. - Europe: strategic investments in fractionation plants support product diversification. - Asia Pacific: growing haemophilia treatment demand in China and India fuels capacity uptake. - Middle East: increasing collaborations improve regional self‐sufficiency in plasma derivatives. - Africa: pilot programs in South Africa strengthen plasma collection infrastructure. - Segment Covers: - Product Type: • Immunoglobulins: high‐volume IVIG therapies for autoimmune disorders. • Albumin: critical care applications in shock treatment. • Clotting Factors: haemophilia A and B management solutions. - Application: • Therapeutics: replacement therapies in immunodeficiency syndromes. • Diagnostics: plasma‐derived reagents for transfusion testing. - End‐User: • Hospitals: primary consumers of albumin and clotting factor concentrates. • Specialty Clinics: immunoglobulin administrations for chronic conditions. Growth Factors: Rising prevalence of immunodeficiency disorders and expanded market scope into recombinant fractions are key market drivers. Global immunoglobulin consumption reached 1,400 tons in 2024, up 8% year-on-year, offering significant market opportunities. Voluntary donor enrollment in North America surged 12% in 2024, driving a 7% uplift in collection volumes. Advanced fractionation capacity—such as the Octapharma Germany facility adding 50,000 L/month in mid-2024—bolstered supply. These drivers present market growth strategies alongside market challenges and restraints, supporting sustainable business growth and a projected 10.8% CAGR through 2032. Book the Latest Edition of this Market Study Get Up to 25 % Discount: Market Trends: Recent market research and market insights reveal accelerated AI-enabled donor screening that reduced deferral rates by 15% in 2024, enhancing supply reliability. Consolidation with regional partners—illustrated by Grifols' 2025 alliance in China—drives consolidation-driven market share shifts. Custom nano-scale chromatography methods achieved a 5% yield gain over conventional fractionation. Pressure from donor deferrals remains a key market restraint, while technological differentiation and regional capacity localization continue to define Blood Plasma Market trends and industry trends. Actionable Insights • Production Capacity: 5.2 M L/month global plasma processing in 2024, supporting an estimated market revenue uplift of USD 2.5 Mn monthly. • Pricing: IVIG average selling price at USD 90/g in Q4 2024, influencing overall market revenue stabilization. • Exports: U.S. plasma exports rose 9% in H2 2024 to 300k L, boosting supplier revenues. • Imports: EU plasma imports grew 11% in Q1 2025, reflecting demand-driven revenue influx. • Use Cases: APAC hospital albumin usage grew 7% in 2024, expanding revenue streams in critical care. • Micro-indicators: emerging nano-fractionation sites ( Key Players: • CSL Behring • Grifols • Takeda Pharmaceutical (formerly Shire) • Octapharma • Kedrion Biopharma • Bio Products Laboratory • LFB Group • Sanquin Plasma Products • China Biologic Products • ADMA Biologics • GC Pharma • CSL Plasma • Emergent BioSolutions • Kamada • Centurion Pharma Get Customization on this Report: Competitive Strategies: • CSL Behring's vertical integration of collection and fractionation in 2024 reduced COGS by 6% and improved margin by 2.3%. • Grifols' alliance with Shandong Weigao expanded plasma centers by 15 sites in China, increasing Asian Blood Plasma Market share. • Takeda's clinical partnerships with rare‐disease clinics in 2024 drove immunoglobulin adoption, boosting U.S. market revenue by 5%. • Kedrion Biopharma's targeted partnerships elevated its industry share among emerging biopharma companies by 3% in 2024. Frequently Asked Questions 1. Who are the dominant players in the Blood Plasma Market? Key players include CSL Behring, Grifols, Takeda, Octapharma, Kedrion Biopharma and others that account for major technological and capacity leadership. 2. What will be the size of the Blood Plasma Market in the coming years? The Blood Plasma Market size is projected to grow from USD 38.8 Mn in 2025 to USD 79.5 Mn by 2032 at a 10.8% CAGR. 3. Which end-user industry has the largest growth opportunity? Hospitals and specialty clinics administering IVIG and clotting factors for immunodeficiency and haemophilia represent the largest growth segments. 4. How will market development trends evolve over the next five years? Trends include AI-driven donor screening, nano-scale fractionation, and regional capacity localization as per the latest Blood Plasma Market report. 5. What is the nature of the competitive landscape and challenges in the Blood Plasma Market? The landscape remains consolidated, with key players pursuing vertical integration, regional alliances and facing donor-recruitment challenges as primary market restraints. 6. What go-to-market strategies are commonly adopted in the Blood Plasma Market? Strategies include strategic partnerships for capacity expansion, targeted clinical collaborations, differentiated fractionation technologies and localized regulatory approvals to drive market opportunities. About Coherent Market Insights Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
